Clinical Review

ABC of heart failure

Management: digoxin and other inotropes, β blockers, and antiarrhythmic and antithrombotic treatment

BMJ 2000; 320 doi: 10.1136/bmj.320.7233.495 (Published 19 February 2000)
Cite this as: BMJ 2000;320:495

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. C R Gibbs,
  2. M K Davies,
  3. G Y H Lip

    Digoxin

    Use of digoxin for heart failure varies between countries across Europe, with high rates in Germany and low rates in the United Kingdom. It is potentially invaluable in patients with atrial fibrillation and coexistent heart failure, improving control of the ventricular rate and allowing more effective filling of the ventricle. Digoxin is also used in patients with chronic heart failure secondary to left ventricular systolic impairment, in sinus rhythm, who remain symptomatic despite optimal doses of diuretics and angiotensin converting enzyme inhibitors, where it acts as an inotrope.

    Digoxin should be considered in patients with sinus rhythm plus (a) continued symptoms of heart failure despite optimal doses of diuretics and angiotensin converting enzyme inhibitors; (b) severe left ventricular systolic dysfunction with cardiac dilatation; or (c) recurrent hospital admissions for heart failure

    Incidence of death or admission to hospital due to worsening heart failure in two groups of patients: those receiving digoxin and those receiving placebo (Digitalis Investigation Group's study—see key references box at end of article)

    Study of effect of digoxin on mortality and morbidity in patients with heart failure*

    Number of participants: 6800

    Design: prospective, randomised, double blind, placebo controlled

    Participants: left ventricular ejection fraction <45%

    Intervention: randomised to digoxin (0.125-0.500 mg) or placebo; follow up at 37 months

    Results:

    • Reduced admissions to hospital owing to heart failure (greater absolute and relative benefits in the patients with resistant symptoms and more severe impairment of left ventricular systolic function)

    • No effect on overall survival

    Evidence of symptomatic benefit from digoxin in patients with chronic heart failure in sinus rhythm has been reported in several randomised placebo controlled trials and several smaller trials. The RADIANCE and PROVED trials, for example, reported that the withdrawal of digoxin from patients with congestive heart failure who had already been treated with the drug was associated with worsening heart failure and increased hospital readmission rates. The Digitalis Investigation Group's …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular